NCT06897501 Postoperative Vocal Cord Palsy Between Double-lumen Endobronchial Tube and Bronchial Blocker for Robot-assisted Esophagectomy
| NCT ID | NCT06897501 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Samsung Medical Center |
| Condition | One Lung Ventillation (OLV) |
| Study Type | INTERVENTIONAL |
| Enrollment | 202 participants |
| Start Date | 2025-04-14 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 202 participants in total. It began in 2025-04-14 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to investigate whether the use of bronchial blocker could reduce the incidence of postoperative vocal cord palsy than the use of double-lumen endobronchial tube in robot-assisted esophagectomy.
Eligibility Criteria
Inclusion Criteria: * Adults aged 19 or older * American Society of Anesthesiologists physical status I - III * Elective robot-assisted esophagectomy * Any clinical stage of esophageal cancer * Patients who need recurrent laryngeal nerve lymph nodes resection Exclusion Criteria: * Patients who diagnosed vocal cord palsy or damage before surgery * Patients who need specific airway device due to airway problem * History of thoracic surgery * Emergency surgery * Combined surgery with other department * Pregnant or nursing women
Contact & Investigator
Hyun Joo Ahn, MD PhD
PRINCIPAL INVESTIGATOR
Samsung Medical Center
Frequently Asked Questions
Who can join the NCT06897501 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying One Lung Ventillation (OLV). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06897501 currently recruiting?
Yes, NCT06897501 is actively recruiting participants. Contact the research team at hyunjooahn@skku.edu for enrollment information.
Where is the NCT06897501 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06897501 clinical trial?
NCT06897501 is sponsored by Samsung Medical Center. The principal investigator is Hyun Joo Ahn, MD PhD at Samsung Medical Center. The trial plans to enroll 202 participants.